SCHEMBL5227731

SCHEMBL5227731

CC(C)(C)OC(=O)NC(C)(C)C(=O)NC(COCc1ccccc1)C(=O)O

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 5/20 0.71
PPARG P37231 4/20 0.65
CTSS P25774 2/20 0.58
FOLH1 Q04609 1/20 0.51
KLK7 P49862 2/20 0.49
KLK5 Q9Y337 2/20 0.49
MME P08473 1/20 0.48
PTPN1 P18031 4/20 0.47
CDC25B P30305 4/20 0.47
PTPN2 P17706 3/20 0.47
CDC25A P30304 2/20 0.47
PTPN6 P29350 1/20 0.47
PTPN11 Q06124 1/20 0.47
ACE P12821 1/20 0.47
RAB9A P51151 1/20 0.46
SYK P43405 1/20 0.45
PPARD Q03181 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5247747 1.00 PPARA (0.71) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL14123544 0.91 PPARA (0.62) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL5247053 0.91 PPARA (0.59) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL5247044 0.91 PPARA (0.59) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL14123546 0.90 PPARA (0.61) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL3365980 0.89 PPARA (0.57) PPARAPPARGCTSSKLK7KLK5
SCHEMBL1132901 0.88 PPARA (0.90) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL828674 0.88 PPARA (0.90) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL17051 0.88 PPARA (0.90) PPARAPPARGCTSSFOLH1KLK7
SCHEMBL6160926 0.85 ACE (0.62) PPARAPPARGCTSSKLK5MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001970-B1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER (US) 2007-03-07 EP claimed
EP-0828754-B1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER (US) 2005-02-02 EP claimed
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure CARPINO PHILIP ALBERT (US) 2004-01-15 US claimed
US-20040006063-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2004-01-08 US claimed
US-20030216399-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2003-11-20 US claimed
US-6429313-B2 Dipeptide derivatives PFIZER INC. 2002-08-06 US claimed
US-20020065284-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-05-30 US claimed
US-20020042415-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-04-11 US claimed
US-20020002165-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2002-01-03 US claimed
US-20010041703-A1 Dipeptide derivatives CARPINO PHILIP ALBERT (US) 2001-11-15 US claimed
EP-1001970-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 2000-05-24 EP claimed
WO-1998058947-A1 DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES PFIZER INC. (US) 1998-12-30 WO claimed
WO-2024217441-A1 GHSR 1A AGONIST, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 长春金赛药业有限责任公司 2024-10-24 WO disclosed
CN-117229280-A Method for preparing capromorelin 洛阳惠中兽药有限公司 2023-12-15 CN disclosed
EP-2852591-A1 L-MALATE SALT OF 2, 7 - DIAZA - SPIRO [4.5]DEC- 7 - YLE DERIVATIVES AND CRYSTALLINE FORMS THEREOF AS GHRELIN RECEPTOR AGONISTS Novartis AG (CH) 2015-04-01 EP disclosed
CN-104271579-A L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists NOVARTIS AG 2015-01-07 CN disclosed
EP-0828754-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER INC. (US) 1998-03-18 EP disclosed
CN-1143647-A Dipeptides which promote release of growth hormone PFIZER (US) 1997-02-26 CN disclosed
WO-1996038471-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER INC. (US) 1996-12-05 WO disclosed
WO-1996035713-A1 DIPEPTIDES WHICH PROMOTE RELEASE OF GROWTH HORMONE PFIZER, INC. (US) 1996-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009984-A1 Increasing levels of endogenous growth hormone, especially treating osterporosis, aging frailty or congestive heart failure GHSR, GHRHR, GIPR PPARA 1592/4885PPARG 238/4885CTSS 850/4885
US-20020042415-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1854/4885PPARG 426/4885CTSS 1873/4885
US-20010041703-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1849/4885PPARG 391/4885CTSS 2159/4885
US-20020002165-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1854/4885PPARG 426/4885CTSS 1873/4885
US-20040006063-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1586/4885PPARG 386/4885CTSS 1947/4885
US-20030216399-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1854/4885PPARG 426/4885CTSS 1873/4885
US-20020065284-A1 Dipeptide derivatives GIPR, GHRHR, GHSR PPARA 1854/4885PPARG 426/4885CTSS 1873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.